U.S. markets open in 20 minutes
  • S&P Futures

    3,844.25
    +16.25 (+0.42%)
     
  • Dow Futures

    31,350.00
    -21.00 (-0.07%)
     
  • Nasdaq Futures

    12,955.25
    +123.50 (+0.96%)
     
  • Russell 2000 Futures

    2,202.00
    +2.00 (+0.09%)
     
  • Crude Oil

    62.50
    -1.03 (-1.62%)
     
  • Gold

    1,759.40
    -16.00 (-0.90%)
     
  • Silver

    26.85
    -0.83 (-3.00%)
     
  • EUR/USD

    1.2130
    -0.0056 (-0.46%)
     
  • 10-Yr Bond

    1.4650
    -0.0530 (-3.49%)
     
  • Vix

    27.91
    +6.57 (+30.79%)
     
  • GBP/USD

    1.3970
    -0.0042 (-0.30%)
     
  • USD/JPY

    106.3650
    +0.1350 (+0.13%)
     
  • BTC-USD

    46,315.79
    -5,371.96 (-10.39%)
     
  • CMC Crypto 200

    926.05
    -7.09 (-0.76%)
     
  • FTSE 100

    6,538.07
    -113.89 (-1.71%)
     
  • Nikkei 225

    28,966.01
    -1,202.26 (-3.99%)
     

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of OPRA, QD and GERN

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, NY / ACCESSWIRE / February 26, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Opera Limited (OPRA)
Class Period: (a) Opera American depositary shares pursuant and/or traceable to the Company's initial public offering commenced on or about July 27, 2018 and/or (b) Opera securities between July 27, 2018 and January 15, 2020,
Lead Plaintiff Deadline: March 24, 2020

The OPRA lawsuit alleges Opera Limited made materially false and/or misleading statements and/or failed to disclose during the class period that: (i) Opera's sustainable growth and market opportunity for its browser applications was significantly overstated; (ii) Defendants' funded, owned, or otherwise controlled loan services applications and/or businesses relied on predatory lending practices; (iii) all the foregoing, once revealed, were reasonably likely to have a material negative impact on Opera's financial prospects, especially with respect to its lending applications' continued availability on the Google Play Store; and (iv) as a result, the Offering Documents and Defendants' statements were materially false and/or misleading and failed to state information required to be stated therein.

Learn about your recoverable losses in OPRA: http://www.kleinstocklaw.com/pslra-1/opera-limited-loss-submission-form?id=5532&from=1

Qudian Inc. (QD)
Class Period: December 13, 2018 to January 15, 2020
Lead Plaintiff Deadline: March 23, 2020

The QD lawsuit alleges that Qudian Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) regulatory developments in China threatened to negatively impact Qudian's fiscal full-year 2019 ("FY19") financial results; (ii) Qudian's business was unprepared to mitigate the risks associated with these regulatory changes; (iii) as a result, Qudian's loan portfolio was plagued by growing delinquency rates; (iv) all of the foregoing made Qudian's repeated assertions concerning its FY19 financial guidance unrealistic; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in QD: http://www.kleinstocklaw.com/pslra-1/qudian-inc-loss-submission-form?id=5532&from=1

Geron Corporation (GERN)
Class Period: March 19, 2018 to September 26, 2018
Lead Plaintiff Deadline: March 23, 2020

The filed complaint alleges that defendants misled investors regarding a drug called imetelstat, which was intended to treat certain cancers that occur in bone marrow. Specifically, defendants misled investors about the results of a clinical drug study of imetelstat called IMbark. That study was designed to ascertain whether imetelstat helped patients with a cancer called myelofibrosis.

Learn about your recoverable losses in GERN: http://www.kleinstocklaw.com/pslra-1/geron-corporation-et-al-loss-submission-form?id=5532&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm



View source version on accesswire.com:
https://www.accesswire.com/578132/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-OPRA-QD-and-GERN